Drug or intervention
Psilocybin Clinical Trials
Studies that test Psilocybin, alone, with other treatments or as the comparison.
In numbers
Open to volunteers: recruiting, not yet recruiting or enrolling by invitation. Active adds studies under way that have stopped recruiting.
Open to volunteers
All 141Alzheimer's Disease
Neuroplasticity Enhancement From Cognitive Training Reinforced by Psilocybin
Background: Normal aging, as well as dementias such as Alzheimer s disease, can cause changes in the brain that affect memory, attention, and thinking.
- Trial name
- NCT07721467
- Testing
- Psilocybin, Cognitive Training
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- National Institute on Aging (NIA)
Depression, Anxiety, Psilocybin-Assisted Psychotherapy
Psilocybin-Assisted Psychotherapy in Patients With Advanced Cancer on Maintenance Therapy
To learn about the feasibility, safety, and effects of psilocybin-assisted psychotherapy on depression and/or anxiety in participants who are being treated for advanced cancer.
- Conditions
- Depression, Anxiety, Psilocybin-Assisted Psychotherapy, Advanced Cancer
- Trial name
- NCT06200155
- Testing
- Psilocybin, Niacin
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- M.D. Anderson Cancer Center
Depression, Anxiety
TRIPS - Treatment to Improve Depression and/or Anxiety Using Psilocybin-assisted Psychotherapy in Cancer Survivors
This clinical research study is to learn about the feasibility, safety, and effects of psilocybin-assisted psychotherapy for cancer survivors with depression and/or anxiety.
- Conditions
- Depression, Anxiety, Cancer
- Trial name
- NCT06801041
- Testing
- Psilocybin
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- M.D. Anderson Cancer Center
Psilocybin, Neuropathy
NeuroGuard: Psilocybin Trial for Preventing Chemo-induced Neuropathy
To learn if psilocybin can help to prevent or decrease the severity of chemotherapy-induced peripheral neuropathy (CIPN) in patients who are receiving chemotherapy for the treatment of breast, colorectal, and In this study…
- Trial name
- NCT07227909
- Testing
- Psilocybin (drug), Standard of Care (SOC)
- Where
- United States
- Volunteers
- 83 people
- Sponsor
- M.D. Anderson Cancer Center
Major Depressive Disorder (MDD), Depression in Adults
A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder
The purpose of this study is to determine the efficacy, safety and tolerability of CYB003 compared to matching placebo as adjunctive treatment in patients with MDD.
- Conditions
- Major Depressive Disorder (MDD), Depression in Adults, Depression - Major Depressive Disorder, Depression Disorders
- Trial name
- EMBRACE (NCT06793397)
- Testing
- CYB003, Psychological Support
- Where
- 79 sites in United States, Australia and 6 more
- Volunteers
- 330 people
- Sponsor
- Cybin IRL Limited
Early-stage Breast Cancer, Fear of Cancer Recurrence
Psilocybin FCR Early-Stage Breast Cancer
This trial is designed to evaluate efficacy and psychological mechanisms of single-dose psilocybin-assisted psychotherapy (PAP) to treat fear of cancer recurrence (FCR), psychiatric (anxiety, depression) distress and…
- Conditions
- Early-stage Breast Cancer, Fear of Cancer Recurrence, Anxiety, Depression
- Trial name
- NCT07909408
- Testing
- Psilocybin 25 mg, Psilocybin 5 mg
- Where
- 2 sites in United States
- Volunteers
- 100 people
- Sponsor
- NYU Langone Health
Mood (Psychological Function), Well Being
Psilocybin Efficacy With or Without Pimavanserin Pretreatment
Twenty healthy adults (≥21 years old) will be enrolled to evaluate the efficacy of a single oral dose of psilocybin (25 mg) administered with or without pretreatment using oral pimavanserin (34 mg) or placebo.
- Conditions
- Mood (Psychological Function), Well Being, Mood, Healthy
- Trial name
- PRISMatic (NCT07610135)
- Testing
- Psilocybin, Pimavanserin
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
PTSD, PTSD - Post Traumatic Stress Disorder
Assessing of Behavioral Risk and Response to Electromagnetic and Psychedelic Therapies
PRE-EMPT will assemble a cohort of 150 participants from three populations (low risk, intermediate risk, and high risk for self-harm).
- Conditions
- PTSD, PTSD - Post Traumatic Stress Disorder, Major Depression, Suicidality
- Trial name
- PRE-EMPT (NCT07745569)
- Testing
- Transcranial Magnetic Stimulation, Psilocybin (drug), Neurofeedback
- Volunteers
- 150 people
- Sponsor
- University of New Mexico
Well-Being, Psychological, Psychedelic Experiences
Consciousness and Psilocybin Effects on Well-Being: The CoPEWell Study
This study is exploring how psilocybin (a psychedelic drug) may improve mood and wellbeing. Many people report feeling better after taking psilocybin, but it is not clear why.
- Trial name
- NCT07360301
- Testing
- Psilocybin, Clonidine
- Where
- United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- University of Wisconsin, Madison
Transdiagnostic, Depression - Major Depressive Disorder
Open-Label Psilocybin Study in Transdiagnostic Population
The primary objective of this study is to investigate the safety, feasibility, and tolerability of psilocybin treatment in individuals with functional impairment due to psychiatric symptoms.
- Conditions
- Transdiagnostic, Depression - Major Depressive Disorder, Anxiety, PTSD Symptoms
- Trial name
- NCT06442423
- Testing
- Psilocybin
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Yale University
Completed, with results posted
All 23Borderline Personality Disorder, Major Depressive Disorder
Psilocybin in Co-occuring Major Depressive Disorder and Borderline Personality Disorder
The primary objective of the study is to evaluate the safety and efficacy of psilocybin in adults with major depressive disorder (MDD) and borderline personality disorder (BPD).
- Trial name
- NCT05399498
- Testing
- Psilocybin
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Chicago
Obsessive-Compulsive Disorder
Efficacy of Psilocybin in OCD: a Double-Blind, Placebo-Controlled Study.
This study aims to investigate the effects of oral psilocybin on OCD symptomatology and provide the first evidence of the neural mechanism that may mediate psilocybin's purported therapeutic effects on OCD.
- Trial name
- NCT03356483
- Testing
- Psilocybin (0.25mg/kg), Niacin (250mg)
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Yale University
Parkinson Disease, Depression
Psilocybin Therapy for Depression and Anxiety in Parkinson's Disease
The purpose of this study is to determine the safety, tolerability, and feasibility of psilocybin therapy for depression and anxiety in people with Parkinson's disease.
- Conditions
- Parkinson Disease, Depression, Anxiety
- Trial name
- PDP1 (NCT04932434)
- Testing
- Psilocybin therapy
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Joshua Woolley, MD, PhD
Major Depressive Disorder
Psilocybin-assisted CBT for Depression
The primary objectives of this clinical investigation are to (1) determine the acceptability and feasibility of joining psilocybin-assisted therapy with cognitive-behavioral therapy (PA-CBT) for patients with depression, (2)…
- Trial name
- NCT05227612
- Testing
- Psilocybin, Cognitive behavioral therapy
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- University of California, Los Angeles
Cocaine-Related Disorders
Psilocybin-facilitated Treatment for Cocaine Use
The primary purpose of this study is to evaluate the feasibility and estimate the efficacy of psilocybin-facilitated treatment for cocaine use.
- Trial name
- NCT02037126
- Testing
- Psilocybin, Diphenhydramine
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Alabama at Birmingham